ArticleTheranostics2021
Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Mitochondria-targeted strategies in cancer radiotherapy: from ROS regulation to immunogenic cell death.Frontiers in cell and developmental biology · 2026Review
- The Synergistic Cytotoxic Effect of the Two Enantiomers of 6‑Prenylflavanones in the HeLa Cell Line.ACS omega · 2025Article
- A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis.Journal of experimental & clinical cancer research : CR · 2025Review
- Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.Science advances · 2025Article
- Combination of Vismodegib and Paclitaxel Enhances Cytotoxicity via Bak-mediated Mitochondrial Damage in EGFR-Mutant Non-Small Cell Lung Cancer Cells.Cell biochemistry and biophysics · 2024Article
- Identification and Analysis of Anticancer Therapeutic Targets from the Polysaccharide Krestin (PSK) and Polysaccharopeptide (PSP) Using Inverse Docking.Molecules (Basel, Switzerland) · 2024Article
- The expression ofFrontiers in endocrinology · 2024Article
- Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Review
- Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.Cancers · 2023Review
- Eltrombopag directly activates BAK and induces apoptosis.Cell death & disease · 2023Article
- A novel defined pyroptosis-related gene signature predicts prognosis and correlates with the tumour immune microenvironment in lung adenocarcinoma.Scientific reports · 2023Article
- Identification of Anoikis-Related Subgroups and Prognosis Model in Liver Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- Footprints: Stamping hallmarks of lung cancer with patient-derived models, from molecular mechanisms to clinical translation.Frontiers in bioengineering and biotechnology · 2023Review
- Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer.Frontiers in immunology · 2023Review
- Characterization of the Second Apoptosis Inhibitor Encoded by Guinea Pig Cytomegalovirus.Journal of virology · 2022Article
- Small molecule SJ572946 activates BAK to initiate apoptosis.iScience · 2022Article
- Identification of a prognostic index system and tumor immune infiltration characterization for lung adenocarcinoma based on mRNA molecular of pyroptosis.Frontiers in medicine · 2022Article
- Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers.Biochemical Society transactions · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Dongkyoo ParkDepartment of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Abu Syed Md AnisuzzamanDepartment of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Andrew T MagisInstitute for Systems Biology, Seattle, WA 98109, USA.
Guo ChenDepartment of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Maohua XieDepartment of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Guojing ZhangDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Madhusmita BeheraDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Gabriel L SicaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Suresh S RamalingamDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Taofeek K OwonikokoDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Xingming DengDepartment of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
Institute for Systems Biology · US
Funding
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5MProject 3: Targeting Bax signaling to overcome treatment resistance in NSCLCP50CA217691 · NCI · EMORY UNIVERSITY · PI SICA, GABRIEL LARKIN · 2019 to 2024
$10.1MStructure-based anti-cancer drug developmentR01CA136534 · NCI · EMORY UNIVERSITY · PI DENG, XINGMING · 2010 to 2020
$3.4MModulation of Mcl-1 for Treatment of Lung CancerR01CA255257 · NCI · EMORY UNIVERSITY · PI DENG, XINGMING · 2021 to 2025
$2.1MModulation of BAK in Lung Cancer TherapeuticsR01CA200905 · NCI · EMORY UNIVERSITY · PI DENG, XINGMING · 2017 to 2021
$1.8MNCI NIH HHS P30 CA138292NCI NIH HHS P50 CA217691NCI NIH HHS R01 CA136534NCI NIH HHS R01 CA200905NCI NIH HHS R01 CA255257
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsApoptosisbcl-2 Homologous Antagonist-Killer ProteinCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsMiceMice, NudeMitochondriaPeptide FragmentsProtein BindingProtein DomainsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Small Molecule LibrariesAntineoplastic AgentsBAK1 protein, humanBak1 protein, mouseBax protein (53-86)bcl-2 Homologous Antagonist-Killer ProteinPeptide FragmentsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Small Molecule LibrariesapoptosisBakBH3 domainlung cancersmall molecule activatortherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.